ArticleJournal of clinical immunology2023

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens.

Sudhir Gupta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.